Yujing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yujing Li has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Yubing Guo
School of Medical Science and Engineering Beijing Institute of Technology Beijing China
5 shared publications Guanghao Wu
School of Medical Science and Engineering Beijing Institute of Technology Beijing China
4 shared publicationsHui Wang
Key Laboratory of Ministry of Education School of Medical Science and Engineering Beijing Institute of Technology Beijing China
3 shared publicationsRan Wei
3 shared publicationsHang Yin
2 shared publications- Huan Meng
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing, China
2 shared publications
Latest Publications
- 19 November 2026
- Published by Wiley in Advanced Healthcare Materials
A Biomimetic Photocatalytic Nanomachine With Core‐Shell Architecture for Synergistic CO Gas Therapy and STING Activation in Triple‐Negative Breast Cancer
Carbon monoxide (CO) is a promising therapeutic agent for aggressive triple‐negative breast cancer (TNBC) with limited effective treatments. Moreover, its precise and safe delivery to tumors remains a challenge. However, conventional CO‐releasing strategies present inefficient substrate supply and poor spatiotemporal control. Here, we report a bioinspired photocatalytic nanomachine (g‐C 3 N 4 ‐Au@Hb@MnCO 3 nanoparticles, CAHM NPs) with a “catalytic core–capture layer mineralization shell” architecture that integrates CO 2 generation, capture, and photocatalytic conversion with Mn 2+ ‐mediated immunomodulation for synergistic antitumor therapy. The system is constructed by immobilizing hemoglobin (Hb) on Au‐deposited graphitic carbon nitride (g‐C 3 N 4 ‐Au), followed by in situ mineralization of a pH‐responsive manganese carbonate (MnCO 3 ) shell. In the acidic tumor microenvironment, MnCO 3 decomposes to release CO 2 and Mn 2+ . The captured CO 2 is efficiently photoreduced to CO under 650 nm laser irradiation, inducing immunogenic cell death, while the released Mn 2+ activates the STING pathway to promote dendritic cell maturation and enhance antitumor immunity. In vitro and in vivo studies demonstrate that CAHM NPs in the Laser group effectively suppress tumor growth and elicit robust immune responses, with minimal toxicity. This work presents a novel strategy for spatially controlled CO therapy combined with STING activation, offering a promising platform for the treatment of TNBC.
- 19 November 2026
- Published by Wiley in Advanced Healthcare Materials
A Biomimetic Photocatalytic Nanomachine With Core‐Shell Architecture for Synergistic CO Gas Therapy and STING Activation in Triple‐Negative Breast Cancer
Carbon monoxide (CO) is a promising therapeutic agent for aggressive triple‐negative breast cancer (TNBC) with limited effective treatments. Moreover, its precise and safe delivery to tumors remains a challenge. However, conventional CO‐releasing strategies present inefficient substrate supply and poor spatiotemporal control. Here, we report a bioinspired photocatalytic nanomachine (g‐C 3 N 4 ‐Au@Hb@MnCO 3 nanoparticles, CAHM NPs) with a “catalytic core–capture layer mineralization shell” architecture that integrates CO 2 generation, capture, and photocatalytic conversion with Mn 2+ ‐mediated immunomodulation for synergistic antitumor therapy. The system is constructed by immobilizing hemoglobin (Hb) on Au‐deposited graphitic carbon nitride (g‐C 3 N 4 ‐Au), followed by in situ mineralization of a pH‐responsive manganese carbonate (MnCO 3 ) shell. In the acidic tumor microenvironment, MnCO 3 decomposes to release CO 2 and Mn 2+ . The captured CO 2 is efficiently photoreduced to CO under 650 nm laser irradiation, inducing immunogenic cell death, while the released Mn 2+ activates the STING pathway to promote dendritic cell maturation and enhance antitumor immunity. In vitro and in vivo studies demonstrate that CAHM NPs in the Laser group effectively suppress tumor growth and elicit robust immune responses, with minimal toxicity. This work presents a novel strategy for spatially controlled CO therapy combined with STING activation, offering a promising platform for the treatment of TNBC.
- 3 November 2026
- Published by Wiley in Advanced Healthcare Materials
Hypoxia‐Guided Magnetic Catheter for Localization and Minimally Invasive Intervention in Early‐Stage Lung Cancer
To enable the precise localization and minimally invasive treatment of early‐stage pulmonary lesions, we developed a magnetic catheter system integrating magnetic navigation, hypoxia fluorescence imaging, and multifunctional minimally invasive intervention. The distal end of the system incorporates multiple permanent magnets, a miniature camera equipped with an optical filter, multiple fiber‐optic channels, and a flexibly switchable multifunctional working channel. Under a 40 mT magnetic field applied perpendicular to the initial catheter axis, the catheter incorporating 2.0 mm‐diameter magnets achieved a bending angle of 39.63° ± 2.47° and successfully navigated to multiple designated branches in the bronchial phantom. A proof‐of‐concept model was established using A549 lung cancer spheroids labeled with hypoxia‐responsive fluorescent probes, enabling fluorescence‐guided localization of simulated hypoxic lesions. In the bronchial phantom, the system successfully identified simulated hypoxic lesions and subsequently performed biopsy sampling, simulated drug delivery, and localized laser irradiation. The system was further evaluated in porcine lungs to demonstrate its navigation and localized intervention capabilities. This magnetic catheter system provides a new technological strategy for the precise localization and in situ treatment of early‐stage lung cancer.
- 3 November 2026
- Published by Wiley in Advanced Healthcare Materials
Hypoxia‐Guided Magnetic Catheter for Localization and Minimally Invasive Intervention in Early‐Stage Lung Cancer
To enable the precise localization and minimally invasive treatment of early‐stage pulmonary lesions, we developed a magnetic catheter system integrating magnetic navigation, hypoxia fluorescence imaging, and multifunctional minimally invasive intervention. The distal end of the system incorporates multiple permanent magnets, a miniature camera equipped with an optical filter, multiple fiber‐optic channels, and a flexibly switchable multifunctional working channel. Under a 40 mT magnetic field applied perpendicular to the initial catheter axis, the catheter incorporating 2.0 mm‐diameter magnets achieved a bending angle of 39.63° ± 2.47° and successfully navigated to multiple designated branches in the bronchial phantom. A proof‐of‐concept model was established using A549 lung cancer spheroids labeled with hypoxia‐responsive fluorescent probes, enabling fluorescence‐guided localization of simulated hypoxic lesions. In the bronchial phantom, the system successfully identified simulated hypoxic lesions and subsequently performed biopsy sampling, simulated drug delivery, and localized laser irradiation. The system was further evaluated in porcine lungs to demonstrate its navigation and localized intervention capabilities. This magnetic catheter system provides a new technological strategy for the precise localization and in situ treatment of early‐stage lung cancer.
- Open Access
- 21 July 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (32) , e71473
Development of a Novel Fluorescent Recognition Guidewire System Toward Early Lung Cancer Biopsy
Obtaining tissue biopsies from peripheral pulmonary lesions remains challenging due to the limited maneuverability of conventional bronchoscopic instruments in distal airways and the inability to distinguish malignant from benign tissue in real time. Here, we present a proof‐of‐concept guidewire‐based biopsy system that integrates magnetic actuation for flexible navigation with fluorescence imaging for targeted lesion identification. The system comprises a magnetically driven biopsy tool, a miniaturized camera with an optical filter, a 488 nm laser fiber for fluorescence excitation, and a white‐light illumination fiber. Under external magnetic field control (10–40 mT), the system achieved a maximum deflection angle of 32.60° ± 1.03° (90° magnetic field) and successfully navigated through a scaled bronchial phantom to reach multiple target branches. Using FITC‐conjugated anti‐EGFR antibody‐labeled A549 cell spheroids as simulated tumor targets, the system demonstrated real‐time fluorescence identification and targeted biopsy, recovering 23.40% ± 2.63% of spheroid cells per sampling session. Navigation and biopsy capabilities were further validated in ex vivo porcine lungs. This integrated approach addresses both the navigation and target identification challenges inherent in peripheral lung biopsy and provides a foundation for future development toward clinical application.
- 21 July 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (32) , e71473
Open AccessDevelopment of a Novel Fluorescent Recognition Guidewire System Toward Early Lung Cancer Biopsy
Obtaining tissue biopsies from peripheral pulmonary lesions remains challenging due to the limited maneuverability of conventional bronchoscopic instruments in distal airways and the inability to distinguish malignant from benign tissue in real time. Here, we present a proof‐of‐concept guidewire‐based biopsy system that integrates magnetic actuation for flexible navigation with fluorescence imaging for targeted lesion identification. The system comprises a magnetically driven biopsy tool, a miniaturized camera with an optical filter, a 488 nm laser fiber for fluorescence excitation, and a white‐light illumination fiber. Under external magnetic field control (10–40 mT), the system achieved a maximum deflection angle of 32.60° ± 1.03° (90° magnetic field) and successfully navigated through a scaled bronchial phantom to reach multiple target branches. Using FITC‐conjugated anti‐EGFR antibody‐labeled A549 cell spheroids as simulated tumor targets, the system demonstrated real‐time fluorescence identification and targeted biopsy, recovering 23.40% ± 2.63% of spheroid cells per sampling session. Navigation and biopsy capabilities were further validated in ex vivo porcine lungs. This integrated approach addresses both the navigation and target identification challenges inherent in peripheral lung biopsy and provides a foundation for future development toward clinical application.
- 30 May 2026
- Published by Wiley in Responsive Materials
- Vol. 4 (2)
Front Cover
- Open Access
- 3 April 2026
- Published by Wiley in Responsive Materials
- Vol. 4 (2) , e70055
The scale matters: A review on stimuli‐responsive microrobots categorized by scale for biomedical applications
Microrobots based on responsive materials have pioneered a new paradigm for disease treatment. However, the field currently lacks clear scale‐dependent design principles, often conflating robots ranging from micrometers to centimeters in size. This review addresses this conceptual ambiguity by proposing a well‐defined multi‐scale classification based on the characteristic dimensions of microrobots—millimeter scale, sub‐millimeter scale, micrometer scale, and nanometer scale. Starting from responsive materials, we systematically analyze how each scale dictates fundamental choices in design feature, manufacturing technology, driving mechanism, and control strategy, which are inherently governed by scale‐dominated physical principles. Furthermore, the application of scale‐determined operation modes of microrobots across different stages of medical intervention is explored, clarifying how size empowers each group with unique functionalities. This review clarifies the concept of scale and examines the literature on robots developed between 1 μm and 1 cm, excluding those at the nanoscale.
- 3 April 2026
- Published by Wiley in Responsive Materials
- Vol. 4 (2) , e70055
Open AccessThe scale matters: A review on stimuli‐responsive microrobots categorized by scale for biomedical applications
Microrobots based on responsive materials have pioneered a new paradigm for disease treatment. However, the field currently lacks clear scale‐dependent design principles, often conflating robots ranging from micrometers to centimeters in size. This review addresses this conceptual ambiguity by proposing a well‐defined multi‐scale classification based on the characteristic dimensions of microrobots—millimeter scale, sub‐millimeter scale, micrometer scale, and nanometer scale. Starting from responsive materials, we systematically analyze how each scale dictates fundamental choices in design feature, manufacturing technology, driving mechanism, and control strategy, which are inherently governed by scale‐dominated physical principles. Furthermore, the application of scale‐determined operation modes of microrobots across different stages of medical intervention is explored, clarifying how size empowers each group with unique functionalities. This review clarifies the concept of scale and examines the literature on robots developed between 1 μm and 1 cm, excluding those at the nanoscale.
- 27 March 2026
- Published by Wiley in Macromolecular Rapid Communications
- Vol. 47 (11) , e70263
A Photothermal‐Responsive, Self‐Contractile, and Highly Adhesive Double‐Network Hydrogel
Existing dressings primarily rely on biochemical mechanisms, such as protective functions and drug loading, to promote healing; however, they are often suboptimal in chronic wound repair. PNIPAm‐based hydrogels, with their thermo‐responsive self‐contraction properties, offer a non‐pharmaceutical, mechanically regulated repair solution. However, their contraction behavior is highly dependent on body temperature conduction, which can be intermittent, making it difficult to meet the repair needs of complex wounds. To address this issue, in this study, a photothermal dual‐responsive PNIPAm‐CMCS@TA‐Mg 2+ (PCTM) dual‐network hydrogel was developed. The TA‐Mg 2+ complex network provides precise temperature control through photothermal conversion and enhances adhesion and structural stability in collaboration with CMCS. The PNIPAm network achieves photothermal self‐contraction and volume regulation through thermally sensitive phase transitions. Through the synergistic effect of photothermal regulation and thermally sensitive phase transitions, the hydrogel achieved a volume contraction of 54.8% and its swelling ratio decreased by 32.41% at 37°C, with an adhesion strength of up to 42.8 kPa. After 10 min of near‐infrared (808 nm) light irradiation, the volume contraction rate increased to 65.78%. This study provides an intelligent material solution for complex wound repair through a photothermal‐thermally sensitive synergistic mechanism, significantly enhancing the precision and adaptability of mechanically regulated repair.
- 27 March 2026
- Published by Wiley in Macromolecular Rapid Communications
- Vol. 47 (11) , e70263
A Photothermal‐Responsive, Self‐Contractile, and Highly Adhesive Double‐Network Hydrogel
Existing dressings primarily rely on biochemical mechanisms, such as protective functions and drug loading, to promote healing; however, they are often suboptimal in chronic wound repair. PNIPAm‐based hydrogels, with their thermo‐responsive self‐contraction properties, offer a non‐pharmaceutical, mechanically regulated repair solution. However, their contraction behavior is highly dependent on body temperature conduction, which can be intermittent, making it difficult to meet the repair needs of complex wounds. To address this issue, in this study, a photothermal dual‐responsive PNIPAm‐CMCS@TA‐Mg 2+ (PCTM) dual‐network hydrogel was developed. The TA‐Mg 2+ complex network provides precise temperature control through photothermal conversion and enhances adhesion and structural stability in collaboration with CMCS. The PNIPAm network achieves photothermal self‐contraction and volume regulation through thermally sensitive phase transitions. Through the synergistic effect of photothermal regulation and thermally sensitive phase transitions, the hydrogel achieved a volume contraction of 54.8% and its swelling ratio decreased by 32.41% at 37°C, with an adhesion strength of up to 42.8 kPa. After 10 min of near‐infrared (808 nm) light irradiation, the volume contraction rate increased to 65.78%. This study provides an intelligent material solution for complex wound repair through a photothermal‐thermally sensitive synergistic mechanism, significantly enhancing the precision and adaptability of mechanically regulated repair.
- 9 January 2026
- Published by Elsevier in Nano Today
- Vol. 67
Manganese in metalloimmunotherapy: From molecular targets to material engineering and translational therapeutics
- 9 January 2026
- Published by Elsevier in Nano Today
- Vol. 67
Manganese in metalloimmunotherapy: From molecular targets to material engineering and translational therapeutics
Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric Drug Delivery to Treat Drug Resistant Chondrosarcoma In Vivo
Chondrosarcoma(CS), a prevalent primary malignant bone tumor, frequently exhibits chemotherapy resistance attributed to upregulated anti‐apoptosis pathways such as the Bcl‐2 family. In this manuscript, a new strategy is presented to augment chemosensitivity and mitigate systemic toxicity by harnessing a nano‐enabled drug delivery hydrogel platform. The platform utilizes “PLGA‐PEG‐PLGA”, an amphiphilic triblock copolymer combining hydrophilic polyethylene glycol (PEG) and hydrophobic polylactide glycolide (PLGA) blocks, renowned for its properties conducive to crafting a biodegradable, temperature‐sensitive hydrogel. This platform is tailored to encapsulate a ratiometrically designed dual‐loaded liposomes containing a first‐line chemo option for CS, Doxorubicin (Dox), plus a calculated amount of small molecule inhibitor for anti‐apoptotic Bcl‐2 pathway, ABT‐737. In vitro and in vivo evaluations demonstrate successful Bcl‐2 suppression, resulting in the restoration of Dox sensitivity, evident through impeded tumor growth and amplified necrosis rates at the tumor site. This delivery system showcases remarkable thermal responsiveness, injectability, and biodegradability, all finely aligned with the clinical demands of CS treatment. Collectively, this study introduces a transformative avenue for tackling drug resistance in CS chemotherapy, offering significant clinical potential.
Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric Drug Delivery to Treat Drug Resistant Chondrosarcoma In Vivo
Chondrosarcoma(CS), a prevalent primary malignant bone tumor, frequently exhibits chemotherapy resistance attributed to upregulated anti‐apoptosis pathways such as the Bcl‐2 family. In this manuscript, a new strategy is presented to augment chemosensitivity and mitigate systemic toxicity by harnessing a nano‐enabled drug delivery hydrogel platform. The platform utilizes “PLGA‐PEG‐PLGA”, an amphiphilic triblock copolymer combining hydrophilic polyethylene glycol (PEG) and hydrophobic polylactide glycolide (PLGA) blocks, renowned for its properties conducive to crafting a biodegradable, temperature‐sensitive hydrogel. This platform is tailored to encapsulate a ratiometrically designed dual‐loaded liposomes containing a first‐line chemo option for CS, Doxorubicin (Dox), plus a calculated amount of small molecule inhibitor for anti‐apoptotic Bcl‐2 pathway, ABT‐737. In vitro and in vivo evaluations demonstrate successful Bcl‐2 suppression, resulting in the restoration of Dox sensitivity, evident through impeded tumor growth and amplified necrosis rates at the tumor site. This delivery system showcases remarkable thermal responsiveness, injectability, and biodegradability, all finely aligned with the clinical demands of CS treatment. Collectively, this study introduces a transformative avenue for tackling drug resistance in CS chemotherapy, offering significant clinical potential.
- 29 December 2023
- Published by Wiley in Advanced Materials
- Vol. 36 (15) , e2309591
Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel‐Mediated Reprogramming of Cancer‐Associated Fibroblasts in Osteosarcoma
In osteosarcoma, immunotherapy often faces hurdles posed by cancer‐associated fibroblasts (CAFs) that secrete dense extracellular matrix components and cytokines. Directly removing CAFs may prove ineffective and even promote tumor metastasis. To address this challenge, a sequential nanocomposite hydrogel that reshapes CAF behavior is developed, enhancing tumor‐infiltrating T‐cells in osteosarcoma. The approach utilizes an injectable blend of carboxymethyl chitosan and tetrabasic polyethylene glycol, forming a hydrogel for controlled release of a potent CAF suppressor (Nox4 inhibitor, Nox4i) and liposomal Doxorubicin (L‐Dox) to induce immunogenic cell death (ICD) upon in situ administration. Nox4i effectively counters CAF activation, overcoming T‐cell exclusion mechanisms, followed by programmed L‐Dox release for ICD induction in stroma‐rich osteosarcoma models. Combining the co‐delivery gel with αPD‐1 checkpoint inhibitor further enhances its effectiveness in an orthotopic osteosarcoma model. Immunophenotyping data underscore a significant boost in tumor T‐cell infiltration and favorable anti‐tumor immunity at the whole‐animal level.
- 29 December 2023
- Published by Wiley in Advanced Materials
- Vol. 36 (15) , e2309591
Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel‐Mediated Reprogramming of Cancer‐Associated Fibroblasts in Osteosarcoma
In osteosarcoma, immunotherapy often faces hurdles posed by cancer‐associated fibroblasts (CAFs) that secrete dense extracellular matrix components and cytokines. Directly removing CAFs may prove ineffective and even promote tumor metastasis. To address this challenge, a sequential nanocomposite hydrogel that reshapes CAF behavior is developed, enhancing tumor‐infiltrating T‐cells in osteosarcoma. The approach utilizes an injectable blend of carboxymethyl chitosan and tetrabasic polyethylene glycol, forming a hydrogel for controlled release of a potent CAF suppressor (Nox4 inhibitor, Nox4i) and liposomal Doxorubicin (L‐Dox) to induce immunogenic cell death (ICD) upon in situ administration. Nox4i effectively counters CAF activation, overcoming T‐cell exclusion mechanisms, followed by programmed L‐Dox release for ICD induction in stroma‐rich osteosarcoma models. Combining the co‐delivery gel with αPD‐1 checkpoint inhibitor further enhances its effectiveness in an orthotopic osteosarcoma model. Immunophenotyping data underscore a significant boost in tumor T‐cell infiltration and favorable anti‐tumor immunity at the whole‐animal level.
- Top Cited Papers
- 11 January 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 230, 123231
Electroactive injectable hydrogel based on oxidized sodium alginate and carboxymethyl chitosan for wound healing
- 11 January 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 230, 123231
Top Cited PapersElectroactive injectable hydrogel based on oxidized sodium alginate and carboxymethyl chitosan for wound healing